Triple
T15982890
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Vertex Pharmaceuticals |
E387617
|
entity |
| Predicate | notableProduct |
P1448
|
FINISHED |
| Object |
lumacaftor/ivacaftor
Lumacaftor/ivacaftor is a combination cystic fibrosis medication that improves the function of defective CFTR proteins in patients with specific genetic mutations.
|
E1189576
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: lumacaftor/ivacaftor | Statement: [Vertex Pharmaceuticals, notableProduct, lumacaftor/ivacaftor]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: lumacaftor/ivacaftor Context triple: [Vertex Pharmaceuticals, notableProduct, lumacaftor/ivacaftor]
-
A.
ivacaftor
Ivacaftor is a precision medicine drug used to treat certain forms of cystic fibrosis by improving the function of defective CFTR proteins.
-
B.
Trikafta
Trikafta is a breakthrough combination therapy for cystic fibrosis that targets the underlying genetic defect to improve lung function and reduce symptoms in eligible patients.
-
C.
CFTR
CFTR is a Canadian AM radio station based in Toronto, Ontario, best known for its all-news format and branding as CityNews 680.
-
D.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
E.
Kalydeco
Kalydeco is a prescription medication used to treat certain forms of cystic fibrosis by improving the function of defective CFTR proteins.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: lumacaftor/ivacaftor Triple: [Vertex Pharmaceuticals, notableProduct, lumacaftor/ivacaftor]
Generated description
Lumacaftor/ivacaftor is a combination cystic fibrosis medication that improves the function of defective CFTR proteins in patients with specific genetic mutations.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: lumacaftor/ivacaftor Target entity description: Lumacaftor/ivacaftor is a combination cystic fibrosis medication that improves the function of defective CFTR proteins in patients with specific genetic mutations.
-
A.
ivacaftor
Ivacaftor is a precision medicine drug used to treat certain forms of cystic fibrosis by improving the function of defective CFTR proteins.
-
B.
Trikafta
Trikafta is a breakthrough combination therapy for cystic fibrosis that targets the underlying genetic defect to improve lung function and reduce symptoms in eligible patients.
-
C.
CFTR
CFTR is a Canadian AM radio station based in Toronto, Ontario, best known for its all-news format and branding as CityNews 680.
-
D.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
E.
Kalydeco
Kalydeco is a prescription medication used to treat certain forms of cystic fibrosis by improving the function of defective CFTR proteins.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d86da94ccc819083d187f5dc6a123e |
completed | April 10, 2026, 3:25 a.m. |
| NER | Named-entity recognition | batch_69e15755b5548190acfa29eecb11e675 |
completed | April 16, 2026, 9:40 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69ffcf1abad48190a42510605c30d0b3 |
completed | May 10, 2026, 12:19 a.m. |
| NEDg | Description generation | batch_69ffd049952081909221df73d3555557 |
completed | May 10, 2026, 12:24 a.m. |
| NED2 | Entity disambiguation (via description) | batch_69ffd10ab484819089cd94ef07cb8de5 |
completed | May 10, 2026, 12:27 a.m. |
Created at: April 10, 2026, 4:54 a.m.